Overview

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

Status:
Completed
Trial end date:
2016-05-25
Target enrollment:
Participant gender:
Summary
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Antibodies, Monoclonal